Short description: Chemical compound
2-(Ethylamino)-1,2-diphenylethanone |
| Clinical data |
|---|
| ATC code | |
|---|
| Identifiers |
|---|
IUPAC name
2-(ethylamino)-1,2-diphenylethanone
|
| CAS Number | - 22312-16-9
Y
|
|---|
| PubChem CID | |
|---|
| UNII | |
|---|
| Chemical and physical data |
|---|
| Formula | C16H17NO |
|---|
| Molar mass | 239.318 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
SMILES
CCNC(C1=CC=CC=C1)C(=O)C2=CC=CC=C2
|
InChI
InChI=1S/C16H17NO/c1-2-17-15(13-9-5-3-6-10-13)16(18)14-11-7-4-8-12-14/h3-12,15,17H,2H2,1H3 Key:NHNVMSYWZNJBOO-UHFFFAOYSA-N
|
2-(Ethylamino)-1,2-diphenylethanone (also known as α-ethylamino-deoxybenzoin, [α-(Ethylamino)benzyl]-(phenyl)-ketone and βk-Ephenidine) is a chemical compound which was first invented in 1955,[1] researched by ICI in 1969 as an antidepressant,[2] and subsequently claimed by AstraZeneca as an inhibitor of the enzyme 11β-Hydroxysteroid dehydrogenase type 1.[3] No other pharmacological data has been disclosed, though its chemical structure closely resembles that of certain designer drug compounds such as ephenidine and N-ethylhexedrone.
See also
- α-PCYP
- Fluorolintane
- Indapyrophenidone
- Lefetamine
- UWA-001
References
- ↑ "Über α-Alkylamino-ketone.". Helvetica Chimica Acta 38 (6): 1415–1420. 1955. doi:10.1002/hlca.19550380613.
- ↑ Gilman DJ, "Desyl amines and compositions thereof. gdate = 19 February 1969", GB patent 1143263, assigned to ICI Ltd.
- ↑ Barton P, Clarke D, Davies C, Hargreaves R, Pease J, Rankine M, "Ketones", US patent Abandoned 2005272036, published 8 December 2005, assigned to AstraZeneca AB
 | Original source: https://en.wikipedia.org/wiki/2-(Ethylamino)-1,2-diphenylethanone. Read more |